Dose-dependent effects of omega-3 polyunsaturated fatty acids on C-reactive protein concentrations in cardiometabolic disorders: a dose-response meta-analysis of randomized clinical trials.

IF 4.6 2区医学 Q2 IMMUNOLOGY

Inflammopharmacology Pub Date : 2025-05-01 Epub Date: 2025-04-22 DOI:10.1007/s10787-025-01744-8

Manoochehr Amin Amlashi, Atefeh Payahoo, Saber Jafari Maskouni, Elaheh Dehghani, Mahtab Karami Talandashti, Yeganeh Ghelichi, Mahya Nikoumanesh, Soroush Rezvani, Hossein Shahinfar, Farzad Shidfar

{"title":"Dose-dependent effects of omega-3 polyunsaturated fatty acids on C-reactive protein concentrations in cardiometabolic disorders: a dose-response meta-analysis of randomized clinical trials.","authors":"Manoochehr Amin Amlashi, Atefeh Payahoo, Saber Jafari Maskouni, Elaheh Dehghani, Mahtab Karami Talandashti, Yeganeh Ghelichi, Mahya Nikoumanesh, Soroush Rezvani, Hossein Shahinfar, Farzad Shidfar","doi":"10.1007/s10787-025-01744-8","DOIUrl":null,"url":null,"abstract":"Background: Based on current knowledge, omega-3 fatty acids help to reduce the concentration of C-reactive protein (CRP). However, the dose-response effect and the strength of this effect are not entirely clear.Methods: We systematically searched and screened databases to include eligible studies. This study incorporates a random effect, as well as dose-response meta-analyses using a restricted cubic spline model.Results: Forty randomized clinical trials were analyzed. Results demonstrated significant non-linear dose-response efficacy in the reduction of CRP concentration in patients with cardiovascular disease, metabolic syndrome, and hypertension up to 1200 mg/day of EPA and DHA. In addition, there was a linear decrease in CRP concentration in the dyslipidemia population. The meta-analysis results did not show any significant reduction of CRP in overweight and obese participants, and the dose-response analysis failed to show any apparent reduction. In type 2 diabetes, pooling the results revealed a significant reduction in CRP; however, the combination of EPA and DHA failed to show significant dose-response efficacy in changing CRP concentration.Conclusion: 1200 mg/day of EPA and DHA may help to reduce CRP concentration in patients with cardiometabolic disorders. This reduction is clinically significant, and thus intervention with omega-3 fatty acids should be considered for this population.","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"2325-2339"},"PeriodicalIF":4.6000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10787-025-01744-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Based on current knowledge, omega-3 fatty acids help to reduce the concentration of C-reactive protein (CRP). However, the dose-response effect and the strength of this effect are not entirely clear.

Methods: We systematically searched and screened databases to include eligible studies. This study incorporates a random effect, as well as dose-response meta-analyses using a restricted cubic spline model.

Results: Forty randomized clinical trials were analyzed. Results demonstrated significant non-linear dose-response efficacy in the reduction of CRP concentration in patients with cardiovascular disease, metabolic syndrome, and hypertension up to 1200 mg/day of EPA and DHA. In addition, there was a linear decrease in CRP concentration in the dyslipidemia population. The meta-analysis results did not show any significant reduction of CRP in overweight and obese participants, and the dose-response analysis failed to show any apparent reduction. In type 2 diabetes, pooling the results revealed a significant reduction in CRP; however, the combination of EPA and DHA failed to show significant dose-response efficacy in changing CRP concentration.

Conclusion: 1200 mg/day of EPA and DHA may help to reduce CRP concentration in patients with cardiometabolic disorders. This reduction is clinically significant, and thus intervention with omega-3 fatty acids should be considered for this population.

查看原文本刊更多论文

ω -3多不饱和脂肪酸对心脏代谢紊乱患者c反应蛋白浓度的剂量依赖性影响：随机临床试验的剂量-反应荟萃分析

背景：根据目前的知识，omega-3脂肪酸有助于降低c反应蛋白（CRP）的浓度。然而，剂量-反应效应和这种效应的强度并不完全清楚。方法：我们系统地检索和筛选数据库以纳入符合条件的研究。这项研究结合了随机效应，以及使用限制三次样条模型的剂量-反应荟萃分析。结果：对40项随机临床试验进行分析。结果显示，在心血管疾病、代谢综合征和高血压患者中，当EPA和DHA达到1200mg /天时，CRP浓度的降低具有显著的非线性剂量反应效应。此外，在血脂异常人群中，CRP浓度呈线性下降。荟萃分析结果没有显示超重和肥胖参与者的CRP有任何显著降低，剂量反应分析也没有显示任何明显的降低。在2型糖尿病中，汇总结果显示CRP显著降低；然而，EPA和DHA联合使用在改变CRP浓度方面没有表现出显著的剂量效应。结论：1200mg /d的EPA和DHA可能有助于降低心脏代谢障碍患者的CRP浓度。这种减少具有临床意义，因此应该考虑对这一人群使用omega-3脂肪酸进行干预。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Inflammopharmacology IMMUNOLOGYTOXICOLOGY-TOXICOLOGY

CiteScore

8.00

自引率

3.40%

发文量

200

期刊介绍： Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas: -Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states -Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs -Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents -Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain -Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs -Muscle-immune interactions during inflammation [...]